BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 4
• 5
• 7
• 8
• 9
• 10
• 11
• 12
• 14
• 15
• 16
• 17
• 18
• 19
• 21
• 22
• 23
• 24
• 25
• 26
• 28
• 29
• 30

• Press Releases

  Triveni Bio Raises $65 Million Series C Financing to Expand Scope of First-in-Class Bispecific TRIV-573 Clinical Studies and Drive Next-Stage Company Growth

  June 17, 2026

   · 

  3 min read
• Press Releases

  UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

  June 17, 2026

   · 

  12 min read
• Press Releases

  Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

  June 17, 2026

   · 

  3 min read
• Press Releases

  Deciphera Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 INTREPID Study of Sapablursen in Polycythemia Vera

  June 17, 2026

   · 

  6 min read
• Press Releases

  Over-the-Counter (OTC) Drugs Market Growth Accelerates with E-Pharmacy Adoption and Consumer Health Trends; Projected to Reach USD 256.87 Billion by 2035

  June 17, 2026

   · 

  1 min read
• Press Releases

  Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.

  June 17, 2026

   · 

  6 min read
• Press Releases

  Trevi Therapeutics Announces Upcoming June and July 2026 Event Schedule

  June 17, 2026

   · 

  2 min read
• Press Releases

  Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer

  June 17, 2026

   · 

  13 min read
• Press Releases

  Neuron23 to Accelerate Expansion of NEULARK Phase 2 Trial with Support from The Michael J. Fox Foundation

  June 17, 2026

   · 

  6 min read
• 

  Drug Development

  Be Bio bins hemophilia B cell therapy trial—the biotech’s lead program

  Be Biopharma’s terminated trial is the latest setback in the hemophilia space, where companies like Pfizer and BioMarin have opted to pull their respective products from the market after weak traction.

  June 17, 2026

   · 

  2 min read

   · 

  Tristan Manalac